FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...

While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that having MNC stocks in your portfolio is an assurance of growth ...

Racker, E., and Wu, R., in Ciba Foundation Symposium on Regulation of Cell Metabolism, edit. by Wolstenholme, G. E. W., and O'Connor, C. M., 205 (J. and A. Churchill ...

Alnylam’s second showing on this list is for its Sanofi-partnered siRNA therapy fitusiran, which the companies proposed for the treatment of hemophilia A and B. The FDA’s verdict is expected on March ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...

The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 ...